CD33 and acute myeloid leukemia: Additionally, our CAR.CD33 was able to lyse CD33+ primary AML samples in vitro even when expressing CD33 at low levels, as previously reported by Pizzitola et al. [9], a finding attributed to the high affinity of the scFv used in the CAR, as in ours.